BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: El Kassas M, Alboraie M, Omran D, Salaheldin M, Wifi MN, ElBadry M, El Tahan A, Ezzat S, Moaz E, Farid AM, Omar H, Abouelkhair M, Afify S, Elsaeed K, Shazly Y, Doss W, Esmat G. An account of the real-life hepatitis C management in a single specialized viral hepatitis treatment centre in Egypt: results of treating 7042 patients with 7 different direct acting antiviral regimens. Expert Rev Gastroenterol Hepatol. 2018;12:1265-1272. [PMID: 29757684 DOI: 10.1080/17474124.2018.1476137] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 El Kassas M, Hegazy OM, Salah EM. Effect of treating chronic hepatitis C with direct-acting antivirals on extrahepatic cutaneous manifestations. World J Hepatol 2020; 12(10): 841-849 [PMID: 33200021 DOI: 10.4254/wjh.v12.i10.841] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 El Kassas M, Salah E, Gad A, Hosny A. Improvement of sexual dysfunction in patients after treatment of hepatitis C virus using directly acting antivirals. Curr Med Res Opin 2021;37:967-72. [PMID: 33688780 DOI: 10.1080/03007995.2021.1901677] [Reference Citation Analysis]
3 El Kassas M, Eltabbakh M, Elbadry M, Tawheed A, Elbaz T. Establishing a research production line in real-life settings: the case of Hepatitis C management in a viral hepatitis specialized Egyptian center. Curr Med Res Opin 2022;:1-23. [PMID: 35118916 DOI: 10.1080/03007995.2022.2038489] [Reference Citation Analysis]
4 Kamhawy A, Ahmed Said ZN, Abdelhamid SE, El-Sayed M, Eletreby R, Garem HE, El Kassas M, Esmat G. Hepatitis C viral RNA in blood mononuclear cells of patients treated with directly acting antivirals. Arab J Gastroenterol 2021;22:158-63. [PMID: 33820724 DOI: 10.1016/j.ajg.2021.03.001] [Reference Citation Analysis]
5 Omran D, Alboraie M, Zayed RA, Wifi MN, Naguib M, Eltabbakh M, Abdellah M, Sherief AF, Maklad S, Eldemellawy HH, Saad OK, Khamiss DM, El Kassas M. Towards hepatitis C virus elimination: Egyptian experience, achievements and limitations. World J Gastroenterol 2018; 24(38): 4330-4340 [PMID: 30344418 DOI: 10.3748/wjg.v24.i38.4330] [Cited by in CrossRef: 60] [Cited by in F6Publishing: 45] [Article Influence: 15.0] [Reference Citation Analysis]
6 El Kassas M, Alboraie M, Omar H, El Latif YA, Algaber MA, El Tahan A, El Halwagy H, Afify S, Elserafy M, Elsaeed K, Doss W. High success rates for the use of ombitasvir/paritaprevir/ritonavir containing regimens in treatment of naïve and experienced chronic hepatitis C genotype 4: Real world results. J Med Virol 2019. [PMID: 30950069 DOI: 10.1002/jmv.25478] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
7 Abdelkader NAA, Ahmed OA, Sherief AF, Kandil DM, Gado MS, Al Balakosy AM. Evaluation of long-term changes of aspartate—platelet ratio index, FIB4, and liver stiffness in chronic hepatitis C patients successfully treated by direct-acting antivirals. Egypt Liver Journal 2021;11. [DOI: 10.1186/s43066-021-00141-4] [Reference Citation Analysis]
8 El Kassas M, Alboraie M, Naguib M, Omar H, Tahan AE, Moaz I, Abdellah M, Ezzat S, Wifi MN, Sherief AF, Eltabbakh M, Abdelsalam L, Eissa AH, Omran D. A significant upsurge of body mass index in patients with chronic hepatitis C successfully treated with direct-acting antiviral regimens. Turk J Gastroenterol 2019;30:708-13. [PMID: 31418415 DOI: 10.5152/tjg.2019.18514] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 El-kassas M, El-folly R, Aboromia M, Aly H, Bahgat M, Hamed M. Effect of achieving sustained virological response with direct-acting antiviral agents on glycemic control in diabetic patients with chronic hepatitis C infection. Egypt Liver Journal 2022;12. [DOI: 10.1186/s43066-022-00190-3] [Reference Citation Analysis]
10 Rabaan AA, Al-Ahmed SH, Bazzi AM, Alfouzan WA, Alsuliman SA, Aldrazi FA, Haque S. Overview of hepatitis C infection, molecular biology, and new treatment. J Infect Public Health 2020;13:773-83. [PMID: 31870632 DOI: 10.1016/j.jiph.2019.11.015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
11 El-Kassas M, Elakel W, Alboraie M, Ezzat R, Abdelhakam S, Hassany M, Ali-Eldin Z, Sherief AF, Yosry A, El-Serafy M, El-Sayed MH, Waked I, Doss W, Esmat G; Egyptian National Committee for Control of Viral Hepatitis. Egyptian revalidation of non-invasive parameters for predicting esophageal varices in cirrhotic patients: A retrospective study. Arab J Gastroenterol 2022:S1687-1979(22)00030-2. [PMID: 35473688 DOI: 10.1016/j.ajg.2022.04.003] [Reference Citation Analysis]
12 Elbahrawy A, Ibrahim MK, Eliwa A, Alboraie M, Madian A, Aly HH. Current situation of viral hepatitis in Egypt. Microbiol Immunol 2021;65:352-72. [PMID: 33990999 DOI: 10.1111/1348-0421.12916] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]